Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 1.00 |
| ▸ | HTR2C | P28335 | 7/20 | 0.88 |
| ▸ | HRH1 | P35367 | 9/20 | 0.79 |
| ▸ | DRD2 | P14416 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23242546 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL23242510 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL23242586 | 0.94 | HTR2C (1.00) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL23242575 | 0.92 | HTR2A (1.00) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL23242531 | 0.91 | HTR2A (0.84) | HTR2AHTR2CHRH1DRD2 | |
| SCHEMBL23242569 | 0.91 | HTR2A (0.83) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL29800624 | 0.91 | HTR2A (0.83) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL23242511 | 0.91 | HTR2A (0.83) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL23242501 | 0.88 | HTR2A (1.00) | HTR2AHTR2CHRH1DRD2DRD1 | |
| SCHEMBL23242519 | 0.88 | HTR2A (1.00) | HTR2AHTR2CHRH1DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929688-B | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4048667-B1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANOIC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | ALAIRION INC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4048667-A1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANO IC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | Alairion, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114929688-A | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2022-08-19 | — | — | CN | disclosed |